FDA's final rule revising the 21 CFR Part 312 regulation concerning charging patients for investigational new drugs clarifies the circumstances in which charging for an investigational drug may be appropriate and which costs can be recovered. This rule permits charging for a broader range of uses than was previously allowed. Two new categories of expanded access, individual patients and intermediate-size patient populations, are now included. Three circumstances must be met. First, the promising new drug might not otherwise be developed or safety information might not otherwise be obtained without charging for the drug. Second, charging is only permitted for a trial that is necessary for the further development of the drug. Third, charging must be necessary to fund the conduct of the clinical trial.
Why should you attend?
Although the three conditions seem straightforward, the devil, as usual, is in the details. And what a devil! In this webinar we will dissect the regulations for charging for an investigational drug. We will start with FDA's rationale for the expansion, so that a lot of these tricky requirements make more sense. We'll discuss the differences between indirect and direct costs and how these are viewed in terms of charging for the drug. Then there are time limits, population size limits, requirements for progress of the clinical trial, rules for charging for the sponsor's own drug vs. charging for an approved drug obtained from another entity for use as an active control and we'll review the guidelines and provide some practical advice for moving forward in each of these areas.
Once you have got the rules down or at least have your list to follow, there are supporting document requirements. We'll describe those documents with some examples. And just when you think you are ready to support your clinical study by charging for your investigational drug, we'll step back for a moment and consider price setting and the documentation that will require, followed by some advice on how to navigate collaboration with various payment systems (CMS and Insurance).
We'll also need to discuss promotion limitations, liability, interim labeling and overall economic impacts that FDA will consider before final authorization. Detail by detail, this webinar will introduce you to the process of gaining approval to charge for your investigational drug.
Who will benefit?
Dr. Rita Hanover has concurrently held consulting positions for such companies as Pherin Pharmaceuticals, Utah Cancer Specialists, Montgomery-Watson Environmental Engineering, and Planned Parenthood Federation of America. She earned a Regulatory Affairs Certification (RAC) in 2006 through RAPS, and is also a member of the Society of Clinical Research Associates (SOCRA), and the American Statistical Association (AMSTAT).
Participants/Registrants for our live events, may cancel up to 72 hours prior to the start of the live session and ComplyArena will issue a letter of credit to be used towards any of ComplyArena's future events. The letter of credit will be valid for 12 months.
ComplyArena will process refund in cases where the event has been cancelled and is not rescheduled within 90 days from the original scheduled date of the webinar. In case if a live webinar is cancelled, participants/registrants may choose between recorded version of the course or a refund. Refunds will not be processed to participants who do not show up for the webinar. A webinar may be cancelled due to unavoidable circumstances, participants will be notified 24 hours before the scheduled start of the event. Contact us via email: email@example.com or call +1-888-222-5917 (Toll Free).